List of Artificial Intelligence Companies in South Korea - 24

At 1STBIO, we strive to transform the lives of patients by relentlessly discovering and developing novel therapeutics to address areas of significant unmet need. Inspired by science and innovation, we dedicate our expertise and experience in drug development to bring forward a pioneering change.

3billion is revolutionizing the existing methods and procedures to enable more people to benefit from faster and much accurate diagnosis at an affordable cost. [Who is 3billion?] - 3billion provides an AI-driven clinical diagnostic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases for patients and physicians in need. - 3billion reanalyzes the undiagnosed patients’ genomic data every day without any additional charge. About 10% of undiagnosed patients can receive diagnosis by reanalysis. - More than 40,000 rare diseases patients from more than 60 countries have been tested. - More than 93% of acceptance rate on the 3billion’s test report by physicians. - 3billion has been collaborating with 100 medical institutions across 33 countries to make a diagnosis for rare disease patients. [Core Technology Features] - 3billion has expertise in medical genetics. We have streamlined the analysis pipeline using an automated variant prioritization system and are currently leading diagnostic technology by developing a pathogenicity prediction model of human variants. - 3billion devised a variant interpretation system, EVIDENCE, to automate the process. With the help of EVIDENCE, the variant interpretation takes less than 5 minutes per patient on average. - The EVIDENCE produces consistent variant interpretation according to the current medical guideline, ACMG-AMP interpretation guideline. 3billion's medical geneticist gives the diagnosis and confirms reported variants by Sanger validation (Richards S et al, 2015). - The analysis reflects the latest updates on diseases and genetic variants on daily basis. If any diagnosed case is identified through reanalysis, 3billion provides a report without any additional charge. - We offer Whole Exome Sequencing (WES) & Whole Genome Sequencing (WGS) for rare disease diagnosis. - Web-based portal service – easy access from all over the world. For any inquires, please contact us at support@3billion.io

Actnova is a South Korean startup specializing in AI SaaS solutions. The company platform automates the behavioral testing process in clinical and non-clinical fields with artificial intelligence image processing technology. Actnova is also a manufacturer of materials inspection, measurement, and analysis instruments.

We aim to advance current state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient discovery, ultimately leading to high success rates in the clinical phase. Our award-winning AI drug discovery platform enables the direct discovery of high potency drugs that induce desired cellular-level activity with minimal off-target effects and toxicity. AIGEN Sciences will revolutionize AI-based drug discovery.

Technology that leverages customer value. ALPINION's an innovative and recognized ultrasound brand ‘E-CUBE' principles (‘Extreme Clarity', ‘Efficient Workflow', ‘Ergonomic Design') reflect ALPINION's technological philosophy that provides customers with uniform image quality throughout the product lifetime. ALPINION has focused on acoustic engineering and front-end technology since we initiated our ultrasound business. There has traditionally been a strong focus on back-end processing in ultrasound; however, we shifted attention to the front-end with a focus on the signal quality sent to system processors. ALPINION focuses on continuous innovation in acoustic technology. ALPINION has developed a range of transducer array types and applied them to ALPINION's innovative E-CUBE series of ultrasound systems. Based upon proprietary superior acoustic technology, ALPINION continuously strives to expand the medical business from diagnostic ultrasound to therapeutic ultrasound.

AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.

BERTIS Inc.'s proteomics technology provides diagnostic services that detect cancer and various diseases in the early stages. Proteomics is a field that studies the roles of various proteins, their relationships, and their characteristics, and that can research proteins directly involved in disease occurrence and progression, using technology simultaneously analyze hundreds of proteins as accurate and exquisite. About 10 years ago, when there was no interest in proteomics in Korea, BERTIS Inc. pursued proteomics scientific research after seeing the global scaled potential. As a result, We have secured unique technology based on 25 million protein big data and A. I. and have grown into a leading proteomics company in Korea. And now, we are working hard to go beyond the Republic of Korea into a global representative proteomics company. We constantly communicate and endeavor with experts representing each field, including physicians, chemists, biologists, and engineers.

CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as our unique ‘CHA Bio ecosystem': Academic, Research, Medical Network, and Bio-Industry Business, the world's largest cell library, and our independently developed vaccine adjuvant platform. We will leap forward as a true global bio company centered on the third-generation CGT CDMO and global healthcare business.

CJ Bioscience Global No.1 Microbiome Company CJ Bioscience is pioneering development of next-generation biopharmaceuticals for microbiome health with its leading edge in the field of ‘Wellness'. We aim to provide healthcare solutions for unmet medical needs by examining the relationships between human microbiomes and various diseases. In addition, CJ Bioscience, which uses leading world-class bioinformatic analysis technology, will discover promising candidates that can be used in the treatment of incurable diseases, and accelerate the development of new drugs utilizing our ‘Ez-Mx™ Platform' to become the global No. 1 microbiome company. Microbiome We plan to enter clinical trials (Phase 1) of a new drug development pipeline for treatment of immuno-oncology, autoimmune, and CNS (Central Nervous System) diseases and to promote technology export through joint research with Big Pharma. Also, we are constructing a ‘Ez-Mx™ Platform' by expanding on cohort studies (comparative disease research) and securing global microbiome big data. The next generation of genomic analysis We plan to expand our business area from next generation sequencing (NGS)-based microbiome genomic analysis to microbial infection diagnosis. We will further upgrade our state-of-the-art NGS and bioinformatics (BI) total solution services. We are expanding the global business capabilities of EzBioCloud, a global standard bioinformatic analysis service made for researchers combining a curated microbiome database and artificial intelligence (AI) technology, and TrueBacID, the world's first genome-based infection diagnosis service. In addition, through the global launch of Gut Inside, an intestinal.

Clinomics provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology.COVID-19: EUA (02/2021)

About Coreline soft We develop AI-based imaging diagnosis package, specializing in lungs. This includes lung cancer screening(LCS), COPD quantification, and coronary artery calcification (CAC) systems, we call it B3 systems, covering the 3 big diseases in thoracic imaging. More in-depth lung diagnosis products with analysis such as texture analysis for ILD/IPF and pneumonia detection including COVID-19 are soon to be expected.   √ The Official solution provider for the nationwide lung cancer screening program in Korea (K- LUCAS) from 2017, which is the 2nd state-level-reimbursed LCS program following the US from 2015 √ The Official solution provider of 4-ITLR project by the Nelson Team (Erasmus MC and iDNA in the Netherlands), which is a large early detection LCS Trial-based on B3 system. Two hospitals in Germany, DKFZ Heidelberg and Univ Hosp of Essen, are the members of this trial and our systems will be implemented in these hospitals from 2021. √ Imminent Official solution provider for the German Trial by multi-university hospitals which is a pilot project to prove a national support necessary for LCS in Germany. √ Our COPD systems are used by European customers such as NZ Leuven Belgium, Leicester Univ UK, Parma Univ Italy obtaining the appraisal as the best of breed for early detection, phenotyping, surgery support, and etc.

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.

JD Bioscience (JDB) possesses the core technology and experience to design small molecules for the treatment for a variety of diseases. With its ability and expertise, JBD is developing new drug candidates for metabolic-related diseases.

치료 약물이 없는 뇌퇴행성 질환과 암 질환을 타겟으로 한 혁신 신약 개발 전문기업

KoBioLabs is recognized for its international level of microbiome therapeutic technologies. In particular, our researchers have a distinctive position in the microbiology field globally with their presence in the ongoing International Human Microbiome Consortium [IHMC].

Korea University is a higher education institution that offers academic programs and conducts research.

Conquer Cancer through AI. Lunit is a public company that develops medical AI software for cancer screening and treatment. Lunit AI can empower you to enhance diagnostic performance. Our AI for chest x-ray and 2D & 3D mammography has been validated through 100+ publications in peer-reviewed journals such as JAMA Oncology, Lancet Digital Health and Radiology, and is now in use in 3,500+ sites globally. < Lunit AI Suite for Radiology > • Lunit INSIGHT CXR, AI Solution for Chest X-ray • Lunit INSIGHT MMG, AI Solution for Mammography • Lunit INSIGHT DBT, AI Solution for Digital Breast Tomosynthesis • Lunit CXR Triage, AI solution for Chest X-ray Triage *emergency department use, available in the US only *If you are interested in Lunit Oncology, please visit Lunit Oncology’s LinkedIn page.

Novorex is specialized company in the development of new small molecule drugs targeting mostly oncology and neurology diseases using FBDD and artificial intelligence with pharmaceutical experts. Seamless Drug Discovery is performed using cutting-edge technology that considers the entire process of new drug development. We aim to develop high-efficiency new drugs through drug design that combines biophysical analysis and in vitro/in vivo assay.

We are an AI biotech specializing in drug development based on transcriptomic database. We strive to develop treatments for intractable and rare disease both in oncology and non-oncology space. We partner with pharmaceutical companies and i) identify the optimal indications of NCE under development, ii) identify the proper indications for clinical stage failed compounds, iii) screen combination drugs that can significantly increase the efficacy synergistically, iv) finding the optimal cancer biomarker, and v) identifying the primary site for carcinoma of unknown primary. While our AI technology offers platform to minimize cost, time, and risk of clinical failure for drug candidates, our desire to provide alternative cost competitive treatments for patients with rare and intractable disease are embedded in everyone at ONCOCROSS. Accelerate Drug Development with ONCOCROSS.

PharmCADD is a company designed to accelerate drug discovery meanwhile performing a design without building or maintaining the infrastructure associated with high-performance computational resources. The platform for both the design and discovery in the PharmCADD is composed of the state-of-the art technology: AI (Artificial intelligence), Molecular Dynamics (MD), Quantum Calculation (QC), and Network theory. AI, which is data-derived technology emerges as a new trend which could potentially be very revolutionary in our modern world. It enables customers to accelerate the search for a certain or specific drug candidate in the vast existence of chemical space. On the other hand, MD and quantum calculation, physics-based technology, enables the customers to characterize potential drug candidates more precisely. The effective combination of the data-derived and physics-based technologies leads to more accurate and speedier drug discovery.

Surginex is a company that operates a drug discovery platform intended to develop next-generation bio platforms and new drugs. The company specializes in 361 HCT/P allografts and is committed to turning innovative scientific research into practical medical solutions.

Viework creates new values by offering innovative vision and insight for all. Vieworks aspires to make a remarkable contribution to health improvement and industry growth by introducing the best imaging solution with our passion and creative talents, as well as with our imaging technology.